- Home
- / Kolon Life Science
Kolon Life Science
Stock Price
₩18.7 K
2024-10-29
Market Capitalization
₩231.7 B
2024-10-29
Revenue
₩124.6 B
FY, 2023
Kolon Life Science Summary
Company Summary
- Overview
- Kolon Life Science is a cell and gene therapy company. It provides treatment for degenerative arthritis. In addition, the company is engaged in research in the field of gene medicine, including neuropathic pain medicine and anti-cancer drugs.
- Type
- Public
- Status
- Active
- Founded
- 2000
- Website
- https://www.kolonls.co.kr/
- Cybersecurity rating
- ESG rating
Table of Contents
Kolon Life Science Financials
Summary Financials
- Revenue (Q3, 2024)
- ₩35.9B
- Gross profit (Q3, 2024)
- ₩2.2B
- Net income (Q3, 2024)
- (₩12.5B)
- Cash (Q3, 2024)
- ₩13.3B
- EBIT (Q3, 2024)
- (₩9.7B)
- Enterprise value
- $330.9B
Footer menu
Product
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension
Resources
© Craft.co 2026